The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore

This publication has 29 references indexed in Scilit:

• Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan
  Journal of Gastroenterology and Hepatology, 2007
• 50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B
  Journal of Hepatology, 2006
• 743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment
  Journal of Hepatology, 2006
• Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
  Gastroenterology, 2006
• Of Mice and Women: Toward a Mouse Model of Autoimmune Hepatitis * #
  Hepatology, 2005
• 424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB)
  Journal of Hepatology, 2004
• Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
  New England Journal of Medicine, 2004
• The Natural History of Chronic Hepatitis B Virus Infection
  Seminars in Liver Disease, 2004
• Baseline alt predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV)
  Journal of Hepatology, 2002
• Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B
  PharmacoEconomics, 2000